SGHT - NASDAQ
Sight Sciences, Inc.
$4.55
+4.8%Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
At a Glance
Live Snapshotsght
Total Non-Current Liabilities
Last Annual Value
40.33M
3-Year CAGR
5%
5-Year CAGR
-23%
10-Year CAGR
2%
Sight Sciences, Inc. Competitors Analysis of Total Non-Current Liabilities
| Company | Total Non-Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Sight Sciences, Inc. NASDAQ:SGHT | 40.33M | 5.7% | 3.1% | N/A | |
 Owens & Minor, Inc. NYSE:OMI | 2.22B | -0.9% | 12.1% | 11.9% | |
 Forte Biosciences, Inc. NASDAQ:FBRX | 1.04M | N/A | N/A | -22.9% | |
 Hyperfine, Inc. NASDAQ:HYPR | 2.52M | 34.7% | 37.7% | N/A | |
 MaxCyte, Inc. NASDAQ:MXCT | 16.75M | -2.8% | 24.5% | 12.1% | |
 Owlet, Inc. NYSE:OWLT | 5.93M | -40.9% | -17.8% | N/A | |
 Rapid Micro Biosystems, Inc. NASDAQ:RPID | 23.16M | 52.9% | 62.8% | N/A | |
 TriSalus Life Sciences, Inc. NASDAQ:TLSI | 57.69M | 16.0% | 152.6% | N/A | |
 908 Devices Inc. NASDAQ:MASS | 12.31M | -6.3% | -17.1% | N/A | |
 Senseonics Holdings, Inc. NASDAQ:SENS | 40.88M | -21.7% | -35.5% | 10.2% | |
 Viemed Healthcare, Inc. NASDAQ:VMD | 30.37M | 50.7% | 41.6% | 27.7% |
Sight Sciences, Inc. Fair Value Envelope
Related Guides
Continue your SGHT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.